Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Mineralys Therapeutics Inc is for a loss of 98 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $42.00, above its last closing price of $15.42.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.11 | -1.08 | -0.98 | Beat | 9 |
Sep. 30 2024 | -0.87 | -0.83 | -1.13 | Missed | -35.4 |
Jun. 30 2024 | -0.70 | -0.70 | -0.83 | Missed | -18.6 |
Mar. 31 2024 | -0.61 | -0.67 | -0.70 | Missed | -4.8 |
Dec. 31 2023 | -0.82 | -0.61 | Beat | 26.1 | |
Sep. 30 2023 | -0.70 | -0.76 | -0.57 | Beat | 25 |
Jun. 30 2023 | -0.67 | -0.72 | -0.31 | Beat | 56.9 |
Mar. 31 2023 | -0.88 | -0.89 | -0.51 | Beat | 42.7 |
This summary was machine generated May 5 at 20:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)